<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00624936</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-07095</org_study_id>
    <secondary_id>NCI-2011-03146</secondary_id>
    <nct_id>NCT00624936</nct_id>
  </id_info>
  <brief_title>Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes</brief_title>
  <official_title>Phase I Study of Vidaza and Velcade (Bortezomib) in Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as azacytidine work in different ways to stop the&#xD;
      growth of cancer cells, either by killing the cells or by stopping them from dividing.&#xD;
      Bortezomib may stop the growth of cancer cells by blocking blood flow to the cancer and by&#xD;
      blocking some of the enzymes needed for cell growth. Giving azacytidine together with&#xD;
      bortezomib may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when&#xD;
      giving together with azacytidine in treating patients with relapsed or refractory acute&#xD;
      myeloid leukemia or myelodysplastic syndromes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum tolerated dose (MTD) bortezomib in combination with Azacytidine&#xD;
           in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic&#xD;
           syndromes (MDS).&#xD;
&#xD;
        -  To define the specific toxicities and the dose limiting toxicity (DLT) of Azacytidine&#xD;
           plus bortezomib combination.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the overall response rate (ORR).&#xD;
&#xD;
        -  To determine the rate of complete remission (CR) of Azacytidine plus bortezomib in&#xD;
           relapsed/refractory AML and MDS.&#xD;
&#xD;
        -  To correlate the biological activity of Azacytidine as demethylating agent (changes in&#xD;
           target gene methylation and gene expression, DNMT1 protein expression, global&#xD;
           methylation) with clinical endpoints and plasma pharmacokinetics of azacytidine.&#xD;
&#xD;
        -  To characterize the biological activity of bortezomib as a potential demethylating&#xD;
           agent.&#xD;
&#xD;
        -  To correlate intracellular concentration of azacytidine-triphosphate with global DNA&#xD;
           methylation and other biological endpoints as well as clinical response.&#xD;
&#xD;
        -  To explore the biologic role of microRNAs in determining clinical response to the&#xD;
           azacytidine plus bortezomib combination and achievement of the other pharmacodynamic&#xD;
           endpoints.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of bortezomib.&#xD;
&#xD;
      Patients receive azacytidine IV over 30 minutes on days 1-7 and bortezomib IV on days 2 and 5&#xD;
      or on days 2, 5, and 9 or on days 2, 5, 9, and 12. Treatment repeats every 28 days for up to&#xD;
      12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of bortezomib and tipifarnib until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed for at least 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2008</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of bortezomib in combination with azacytidine</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Determine the maximum tolerated dose (MTD) of Velcade (bortezomib, PS-341) in combination with Vidaza in patients with relapsed/refractory acute myeloid leukemia (AML) and Myelodysplastic Syndrome (MDS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Determine the overall response rate (ORR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complete remission</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Determine the rate of complete remission (CR) of Vidaza plus Velcade in relapsed/refractory AML and MDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological activity of azacytidine and bortezomib as demethylating agents</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Correlate the biological activity of Vidaza as demethylating agent (changes in target gene methylation and gene expression, DNMT1 protein expression, global methylation) with clinical endpoints and plasma pharmacokinetics of Vidaza</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of intracellular concentration of azacytidine-triphosphate with global DNA methylation and other biological endpoints as well as clinical response</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Characterize the biological activity of Velcade as a potential demethylating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologic role of microRNAs in determining clinical response to study drugs</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Correlate intracellular concentration of Vidaza-triphosphate with global DNA methylation and other biological endpoints as well as clinical response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of other pharmacodynamic endpoints</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Explore the biologic role of microRNAs in determining clinical response to the Vidaza plus Velcade combination and achievement of the other pharmacodynamic endpoints.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <arm_group>
    <arm_group_label>Vidaza and Velcade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vidaza 75mg/m2 IV over 30 min daily on days 1-7 This dose is the same for all dose levels. Velcade will be given immediately after Vidaza is completed at one of the following dose levels: 1, 2, 3, 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vidaza</intervention_name>
    <description>Vidaza 75mg/m2 IV over 30min daily on days 1-7. This dose is the same for all dose levels.</description>
    <arm_group_label>Vidaza and Velcade</arm_group_label>
    <other_name>Azacitidina</other_name>
    <other_name>Azacitidinum</other_name>
    <other_name>Azacytidine</other_name>
    <other_name>Mylosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
    <description>Dose level 1 Velcade 0.7mg/m2 IVP on days 2 and 5 Dose level 2 Velcade 0.7mg/m2 IVP on days 2, 5, 9, 12 Dose level 3 Velcade 1.0 mg/m2 IVP on days 2, 5, 9, 12 Dose level 4 Velcade 1.3 mg/m2 IVP on days 2, 5, 9, 12</description>
    <arm_group_label>Vidaza and Velcade</arm_group_label>
    <other_name>Bortezomib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients must be &gt;18 with relapsed or refractory acute myeloid leukemia (AML) and high&#xD;
             risk (by IPSS scoring) Myelodysplastic Syndromes (MDS)&#xD;
&#xD;
          -  Patients with secondary AML or therapy related disease (t-AML) are eligible If&#xD;
             decitabine or Vidaza was a prior treatment for MDS or AML patient is eligible.Prior&#xD;
             Velcade is also permitted.&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 6 months for patients with a co-morbid medical illness&#xD;
&#xD;
          -  Total bilirubin &lt; 2.0mg/dL&#xD;
&#xD;
          -  AST/ALT &lt; 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception prior to and during study treatment&#xD;
&#xD;
          -  Ability to understand and willingness to sign the written informed consent document&#xD;
&#xD;
          -  Active infection is allowed provided it is under control&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to azacytidine or bortezomib that are not easily managed&#xD;
&#xD;
          -  Hypersensitivity to bortezomib, boron, or mannitol&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to:&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Serious cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness/social situations that would limit compliance with study&#xD;
&#xD;
          -  Myocardial infarction within 6 months prior to enrollment&#xD;
&#xD;
          -  New York Heart Association (NYHA) Class III or IV congestive heart failure&#xD;
&#xD;
          -  Uncontrolled angina&#xD;
&#xD;
          -  Severe uncontrolled ventricular arrhythmia&#xD;
&#xD;
          -  Electrocardiographic evidence of acute ischemia&#xD;
&#xD;
          -  Active conduction system abnormalities&#xD;
&#xD;
          -  ECG abnormality that is medically relevant&#xD;
&#xD;
          -  Psychiatric conditions that prevent compliance with protocol or consent.&#xD;
&#xD;
          -  Pre-existing neuropathy grade 2 or higher or other serious neurologic toxicity that&#xD;
             would significantly increase risk of complications from bevacizumab therapy&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study&#xD;
&#xD;
          -  Diagnosis or treatment for another malignancy within 3 years of enrollment, with the&#xD;
             exception of any of the following:&#xD;
&#xD;
               -  Complete resected basal cell carcinoma&#xD;
&#xD;
               -  Squamous cell carcinoma of the skin&#xD;
&#xD;
               -  Any in situ malignancy&#xD;
&#xD;
               -  Low-risk prostate cancer after curative therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior decitabine or azacytidine for MDS or AML is allowed&#xD;
&#xD;
          -  Prior bortezomib allowed&#xD;
&#xD;
          -  More than 2 weeks since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas&#xD;
             or mitomycin C)&#xD;
&#xD;
          -  More than 14 days since prior and no concurrent investigational agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William G. Blum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guido Marcucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer@osu.edu</url>
    <description>Jamesline</description>
  </link>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>February 27, 2008</study_first_submitted>
  <study_first_submitted_qc>February 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>myelodysplastic syndromes</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

